Evidence map›Paper›PMID 28717172›Full record

ArticleScientific reports2017

Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone.

Carla López-Causapé, Lea Mette Sommer, Gabriel Cabot, Rosa Rubio, Alain A Ocampo-Sosa, Helle Krogh Johansen, Joan Figuerola, Rafael Cantón, Timothy J Kidd, Soeren Molin and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 1 synthesis or guideline pooled it, 171 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Antimicrobial agents and chemotherapy · 2026
    Article
  4. Clearance of hypermutator XDRASM case reports · 2026
    Article
  5. Article
  6. First nationwide survey onAntimicrobial agents and chemotherapy · 2025
    Article
  7. Article
  8. Evolution of Resistant Mutants inMicroorganisms · 2025
    Article
  9. Article
  10. Article
  11. JAC-antimicrobial resistance · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Antibiotic resistance mediated by gene amplifications.npj antimicrobials and resistance · 2024
    Review
  16. Mechanisms leading toAntimicrobial agents and chemotherapy · 2024
    Article
  17. Molecular characterization of clinically isolatedAntimicrobial agents and chemotherapy · 2024
    Article
  18. Article
  19. Review
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Carla López-CausapéServicio de Microbiología and Unidad de Investigación, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Islas Baleares (IdISBa), Palma de Mallorca, Spain. carla.lopez@ssib.es.
Lea Mette SommerNovo Nordisk Foundation Center for Biosustainability, The Technical University of Denmark, Lingby, Denmark.
Gabriel CabotServicio de Microbiología and Unidad de Investigación, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Islas Baleares (IdISBa), Palma de Mallorca, Spain.
Rosa RubioServicio de Microbiología and Unidad de Investigación, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Islas Baleares (IdISBa), Palma de Mallorca, Spain.
Alain A Ocampo-SosaServicio de Microbiología, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Marqués de Valdecilla, Santander, Spain.
Helle Krogh JohansenNovo Nordisk Foundation Center for Biosustainability, The Technical University of Denmark, Lingby, Denmark.
Joan FiguerolaServicio de Pediatría, Hospital Son Espases, Palma de Mallorca, Spain.
Rafael CantónServicio de Microbiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
Timothy J KiddSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.ORCID 0000-0002-6135-6364
Soeren MolinNovo Nordisk Foundation Center for Biosustainability, The Technical University of Denmark, Lingby, Denmark.
Antonio OliverServicio de Microbiología and Unidad de Investigación, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Islas Baleares (IdISBa), Palma de Mallorca, Spain. antonio.oliver@ssib.es.
Health Research Institute of the Balearic Islands · ESNovo Nordisk Foundation · DKHospital Universitario Son Espases · ESInstituto de Investigación Marqués de Valdecilla · ESInstituto Ramón y Cajal de Investigación Sanitaria · ESThe University of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emergence of epidemic clones and antibiotic resistance development compromises the management of Pseudomonas aeruginosa cystic fibrosis (CF) chronic respiratory infections. Whole genome sequencing (WGS) was used to decipher the phylogeny, interpatient dissemination, WGS mutator genotypes (mutome) and resistome of a widespread clone (CC274), in isolates from two highly-distant countries, Australia and Spain, covering an 18-year period. The coexistence of two divergent CC274 clonal lineages was revealed, but without evident geographical barrier; phylogenetic reconstructions and mutational resistome demonstrated the interpatient transmission of mutators. The extraordinary capacity of P. aeruginosa to develop resistance was evidenced by the emergence of mutations in >100 genes related to antibiotic resistance during the evolution of CC274, catalyzed by mutator phenotypes. While the presence of classical mutational resistance mechanisms was confirmed and correlated with resistance phenotypes, results also showed a major role of unexpected mutations. Among them, PBP3 mutations, shaping up β-lactam resistance, were noteworthy. A high selective pressure for mexZ mutations was evidenced, but we showed for the first time that high-level aminoglycoside resistance in CF is likely driven by mutations in fusA1/fusA2, coding for elongation factor G. Altogether, our results provide valuable information for understanding the evolution of the mutational resistome of CF P. aeruginosa.

Indexed as

Australiabeta-Lactam ResistanceCystic FibrosisDrug Resistance, BacterialFluoroquinolonesHumansMicrobial Sensitivity TestsMutationPenicillin-Binding ProteinsPhylogenyPolymyxinsPrevalencePseudomonas aeruginosaSpainFluoroquinolonesPenicillin-Binding ProteinsPolymyxins

Identifiers

PMID28717172
PMCPMC5514035
OpenAlexW2736277296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.